PreciseDx has raised USD 20.7 million in a Series B funding round led by Eventide Asset Management, with participation from Labcorp, Quest Diagnostics, and GenHenn Capital Venture. This brings the company's total funding to USD 31.5 million.
The funds will be used to advance in-depth clinical trials to validate PreciseBreast (PDxBr), an early-stage risk assessment tool for invasive breast cancer, independent of HER2 and hormone receptor status, in a targeted clinical setting and prepare for market entry.
Analyst QuickTake: In May 2024, Precise DX and COTA partnered with Baptist Health South Florida to assess the performance of PDxBr test for assessing the risk of invasive breast cancer recurrence. The validation assessment was expected to compare PDxBr’s results to traditional pathology reviews and 21-gene assay results. The latest funding is expected to support this clinical trial.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.